Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04016922
Other study ID # Fetal hemodynamics, neonates
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date July 2019
Est. completion date October 2019

Study information

Verified date July 2019
Source Cairo University
Contact Mai Assistant lecturer
Phone 01153304548
Email maielsayed126@gmail.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This study will be conducted to show the effect of different degrees of maternal iron deficiency anemia on fetal hemodynamics and neonatal outcome and to evaluate the effect of treatment.


Description:

Hemoglobin concentration is used to determine the diagnosis and severity of anemia in low resource settings, an indicator that is routinely screened using WHO-defined hemoglobin cutoffs. These thresholds are lower for pregnant women (females ≥ 15 years of age) than non-pregnant women (11.0 g/dl versus 12.0 g/dl). Severity of anemia is determined using additional cutoffs, with severe anemia defined as a hemoglobin level of less than 7.0 g/dl.

Iron deficiency is defined as a condition in which there are no mobilizable iron stores, resulting from a long-term negative iron balance and leading to a compromised supply of iron to the tissues. Finally, the most significant negative consequence of ID is anemia, usually microcytic hypochromic in nature.

IDA has been linked to unfavorable outcomes of pregnancy. It is the most common nutritional disorder in the world affecting two billion people worldwide with pregnant women particularly at risk. According to WHO report, 2001 indicates that IDA is a significant problem throughout the world ranging from 35-75% in developing countries (average 56%) whereas in industrialized countries the average prevalence is 14%.

Distribution of blood flow (between the placental and cerebral regions) is determined with Middle cerebral artery PI/Umbilical artery PI (C/U ratio); this parameter is always > 1.1 during normal pregnancy, but decreases in the case of hypoxia because of umbilical artery resistance index increase (increase in placental resistance) and cerebral resistance index decrease (cerebral vasodilation).

Perinatal morbidity & mortality of IUGR infants is 3-20 times greater than normal infants. These cases may be followed with outpatient monitoring and they often deliver at term. However process is not severe enough to stop fetal growth completely or to deteriorate. The umbilical artery and the middle cerebral artery waveforms may be abnormal, without effect is seen on Doppler and growth until 26-32 weeks gestation; Mild utero-placental insufficiency.

Iron deficiency and iron deficiency anemia during pregnancy are risk factors for preterm delivery, prematurity and small for gestational age birth weight. Iron deficiency has a negative effect on intelligence and behavioral development in the infant. It is essential to prevent iron deficiency in the fetus by preventing iron deficiency in the pregnant woman.

Prevention and control is typically achieved through iron fortification of food staples like flour and rice and/or through administration of iron supplements most often in iron tablets. Although iron supplements are widely available and fortified foods constitute a major component of the diet in the developed world, access is limited in the developing world


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 500
Est. completion date October 2019
Est. primary completion date October 2019
Accepts healthy volunteers
Gender Female
Age group 20 Years to 35 Years
Eligibility Inclusion Criteria:

- Pregnant females aged 20- 35 years.

- Gestational age 32 weeks or more.

- Living singleton fetus.

Exclusion Criteria:

- Multifetal pregnancy.

- Patients with chronic illness or medical disorders other than iron deficiency anemia.

- Patients with history of recurrent perinatal deaths or recent blood transfusion or other vitamin deficiency anemia.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Oral ferrous fumerate for Group A, Parenteral iron sucrose for Group B, Compatible blood transfusion for Group C
Consent, history. US: fetal heart activity, placental site, fetal biometry, AFI, anomalies, Doppler: umbilical artery, MCA, fetal renal artery, C\U ratio. * Maternal Hb,US at time of first visit, 10 days later after initiation of treatment, at EDD . As part of routine medical care of these patients, they are managed as: A: give oral iron in the form of ferrous fumerate with the possible side effects. if Hb returns to normal, continue iron for 3 mon. B: admit to receive IV iron sucrose according to product literature allergic reaction may happen; antiallergic measures. C: give blood transfusion in the form of packed RBC. allergic and pyrogenic reaction and infection may occur. At delivery will be subjected to: examination, investigations, US.

Locations

Country Name City State
Egypt Kasralainy hospital Giza

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

References & Publications (5)

Abu-Ouf NM, Jan MM. The impact of maternal iron deficiency and iron deficiency anemia on child's health. Saudi Med J. 2015 Feb;36(2):146-9. doi: 10.15537/smj.2015.2.10289. Review. — View Citation

Breymann C. Iron Deficiency Anemia in Pregnancy. Semin Hematol. 2015 Oct;52(4):339-47. doi: 10.1053/j.seminhematol.2015.07.003. Epub 2015 Jul 10. Review. — View Citation

Breymann C; Anaemia Working Group. [Current aspects of diagnosis and therapy of iron deficiency anemia in pregnancy]. Praxis (Bern 1994). 2001 Aug 2;90(31-32):1283-91. Review. German. — View Citation

Lee AI, Okam MM. Anemia in pregnancy. Hematol Oncol Clin North Am. 2011 Apr;25(2):241-59, vii. doi: 10.1016/j.hoc.2011.02.001. Review. — View Citation

Rasmussen K. Is There a Causal Relationship between Iron Deficiency or Iron-Deficiency Anemia and Weight at Birth, Length of Gestation and Perinatal Mortality? J Nutr. 2001 Feb;131(2S-2):590S-601S; discussion 601S-603S. doi: 10.1093/jn/131.2.590S. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in fetal vascular doppler parameters. Fetal doppler parameters by resistance index and pulsatility index at first visit and 10 days after recieving treatment and at delivery. 4 months from June 2019 till October 2019
Primary Neonatal birth weight Neonatal birth weight in kilograms 4 months June 2019 till October 2019
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06302010 - The Effect of Stress Ball Intervention During Non-Stress Test on Anxiety and Fetal Well-Being in High-Risk Pregnancy N/A
Not yet recruiting NCT05666297 - Screening of Cardiac Abnormalities in the First Trimester of Pregnancy by Volumetric Acquisition
Recruiting NCT03302663 - The Value of Advanced Imaging Sequences for Fetal MRI in Clinical Practice N/A
Recruiting NCT06405984 - Trans-Abdominal Fetal Pulse Oximetry - EFS-IDE Early Phase 1
Not yet recruiting NCT06056635 - A Prospective Study on the Role of Karl Storz Curved and Straight Fetoscopes (11508AAK and 11506AAK) for Fetoscopic Intrauterine Procedures N/A
Recruiting NCT05747599 - Adapting and Testing a Behavioural Intervention to Prevent FASD and Adverse Infant Outcomes N/A
Suspended NCT04364308 - The Relationship Between Umbilical Cord ph and Feto-maternal Doppler Studies in Scheduled Nonlaboring Term Singleton Caesarean Deliveries
Completed NCT04366076 - Does a Relationship Exist Between Fetal Hiccups and Computerised Cardiotocography Parameters?